gone right for Walgreens. Facing tough headwinds, the brand has been playing catch up to other U.S. pharmacy retailers for years. WSJ’s Joseph Walker on what went wrong for Walgreens and the private equity deal that could sell the company for parts.

See The Journal live! Take our survey!

Further Reading:

- Walgreens Goes From $100 Billion Health Giant to Private-Equity Salvage Project

- The Walgreens Billionaire Watching His Empire Come Apart

Further Listening:

- How Target Got Off Target

- What Went Wrong at Bed Bath & Beyond?

Learn more about your ad choices. Visit megaphone.fm/adchoices

1d:T55d,Years ago, an ailing company like Walgreens Boots Alliance may have seemed like a prime acquisition target for deal-hungry private equity firms. But many have backed away from retail recently, leaving an opening for groups like Sycamore Partners who are willing to buck the trend. Sycamore announced this month that it would take the global pharmacy business private in a $23.7bn debt and equity deal. The FT’s Due Diligence reporter, Amelia Pollard, explains the well-worn playbook that Sycamore has used on past retail companies, and whether it will work this time with a chain that has its own share of unique problems. Clips from Bloomberg, CNBC, CBS- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Retail’s last barbarian:

The Collapse of Walgreens